CA2898431C - Cell compositions derived from dedifferentiated reprogrammed cells - Google Patents

Cell compositions derived from dedifferentiated reprogrammed cells Download PDF

Info

Publication number
CA2898431C
CA2898431C CA2898431A CA2898431A CA2898431C CA 2898431 C CA2898431 C CA 2898431C CA 2898431 A CA2898431 A CA 2898431A CA 2898431 A CA2898431 A CA 2898431A CA 2898431 C CA2898431 C CA 2898431C
Authority
CA
Canada
Prior art keywords
cells
cell
endoderm
heregulin
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2898431A
Other languages
English (en)
French (fr)
Other versions
CA2898431A1 (en
Inventor
Alan D. Agulnick
Olivia Kelly
Yuki OHI
Allan Robins
Thomas Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viacyte Inc
Original Assignee
Viacyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by Viacyte Inc filed Critical Viacyte Inc
Priority to CA3212301A priority Critical patent/CA3212301A1/en
Publication of CA2898431A1 publication Critical patent/CA2898431A1/en
Application granted granted Critical
Publication of CA2898431C publication Critical patent/CA2898431C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2898431A 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells Active CA2898431C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3212301A CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 2013-02-06
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
PCT/US2014/015156 WO2014124172A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3212301A Division CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Publications (2)

Publication Number Publication Date
CA2898431A1 CA2898431A1 (en) 2014-08-14
CA2898431C true CA2898431C (en) 2023-10-17

Family

ID=50239931

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2898431A Active CA2898431C (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
CA3212301A Pending CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3212301A Pending CA3212301A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Country Status (8)

Country Link
EP (1) EP2954045A1 (enExample)
JP (5) JP6517702B2 (enExample)
AU (5) AU2014214879A1 (enExample)
CA (2) CA2898431C (enExample)
HK (1) HK1218139A1 (enExample)
IL (6) IL321825A (enExample)
RU (2) RU2754089C2 (enExample)
WO (1) WO2014124172A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
WO2017180361A1 (en) * 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
EP3690022B1 (en) * 2016-05-18 2026-03-18 Keio University Cell culture medium for culturing organoid, culture method, and organoid
KR102448428B1 (ko) 2017-01-27 2022-09-30 가부시키가이샤 가네카 내배엽계 세포 집단, 및 다능성 세포로부터 3배엽 중 어느 하나의 세포 집단을 제조하는 방법
IL313825B2 (en) 2017-06-14 2025-07-01 Vertex Pharma Devices and methods for administering medications
JP2020527956A (ja) * 2017-07-21 2020-09-17 センマ・セラピューティクス・インコーポレーテッド 幹細胞由来の膵臓ベータ細胞の再凝集
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
TWI862513B (zh) * 2018-09-19 2024-11-21 日商千紙鶴治療公司 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
US12310830B2 (en) 2019-05-31 2025-05-27 W. L. Gore & Associates, Inc. Biocompatible membrane composite
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
EP4596675A4 (en) * 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4794049B2 (ja) * 1999-04-06 2011-10-12 ジェネンテック， インコーポレイテッド 糖尿病治療へのＥｒｂＢレセプターリガンドの使用
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
CA2625883A1 (en) * 2005-10-14 2007-04-26 Regents Of The University Of Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
ES2849181T3 (es) * 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010129294A2 (en) * 2009-04-27 2010-11-11 Schulz Thomas C Small molecules supporting pluripotent cell growth and methods thereof
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
JP7550830B2 (ja) 2024-09-13
HK1218139A1 (zh) 2017-02-03
JP2020178694A (ja) 2020-11-05
RU2018144412A3 (enExample) 2020-02-14
JP2016506736A (ja) 2016-03-07
IL311689A (en) 2024-05-01
JP2025000625A (ja) 2025-01-07
AU2023202507B2 (en) 2025-12-04
AU2014214879A1 (en) 2015-07-30
RU2015131279A (ru) 2017-03-13
WO2014124172A1 (en) 2014-08-14
IL326919A (en) 2026-05-01
JP2019146578A (ja) 2019-09-05
IL311689B2 (en) 2025-12-01
IL311689B1 (en) 2025-08-01
EP2954045A1 (en) 2015-12-16
AU2023202507A1 (en) 2023-05-11
IL283088A (en) 2021-06-30
IL239953A0 (en) 2015-08-31
AU2019201314B2 (en) 2021-10-14
JP6517702B2 (ja) 2019-05-22
IL239953B (en) 2021-05-31
JP7250731B2 (ja) 2023-04-03
RU2754089C2 (ru) 2021-08-26
JP6721752B2 (ja) 2020-07-15
IL290717A (en) 2022-04-01
CA3212301A1 (en) 2014-08-14
RU2675928C2 (ru) 2018-12-25
AU2026201562A1 (en) 2026-03-19
AU2019201314A1 (en) 2019-03-14
RU2018144412A (ru) 2019-03-25
JP2023017838A (ja) 2023-02-07
IL290717B2 (en) 2024-10-01
AU2022200075B2 (en) 2023-02-02
AU2022200075C1 (en) 2023-07-06
CA2898431A1 (en) 2014-08-14
IL290717B1 (en) 2024-06-01
IL283088B (en) 2022-04-01
AU2022200075A1 (en) 2022-02-03
IL321825A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
US20240409900A1 (en) Cell encapsulation device comprising a pancreatic progenitor cell population
AU2023202507B2 (en) Cell compositions derived from dedifferentiated reprogrammed cells
AU2023201602B2 (en) In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells
EP2421957B1 (en) Cell compositions derived from dedifferentiated reprogrammed cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260130